XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.1

Collaborations and Other Arrangements (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 6,805.6	$ 5,859.8
Contract liabilities	346.6		$ 276.8
China
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	362.2	267.3
Outside U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	2,864.3	2,531.0
Jardiance
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	312.0	267.5
Jardiance | Outside U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	160.8	122.9
Trajenta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	94.6	93.2
Basaglar
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	246.6	303.7
Basaglar | Outside U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	71.4	73.3
Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	193.8	139.7
Olumiant® | Outside U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	169.1	128.4
COVID-19 Antibodies
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	810.1	0.0
COVID-19 Antibodies | Outside U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	159.5	0.0
Tyvyt®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	109.7	57.4
Tyvyt® | Outside U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	109.7	$ 57.4
Tanezumab | Outside US And Japan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms, annual net sales threshold (up to)	150.0
Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract liabilities	23.3		29.7
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Jardiance
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	151.2		156.2
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Trajenta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	108.1		114.6
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Basaglar
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	$ (163.3)		$ (168.0)
Royalty Agreement Terms | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, percentage (up to)	20.00%
Milestone Payments, Capitalized as Intangible Assets | Shanghai Junshi Biosciences Co., Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	$ 60.0
Milestone Payments, Capitalized as Intangible Assets | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	210.0
Milestone Payments, Development and Regulatory | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	100.0
Milestone Payments, Development and Regulatory | Tanezumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	147.5
Milestone Payments, Development and Regulatory | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	85.0
Milestone Payments, Sales-based | Shanghai Junshi Biosciences Co., Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	120.0
Milestone Payments, Sales-based | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	150.0
Milestone Payments, Sales-based | Tanezumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	1,230.0
Milestone Payments, Sales-based | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	1,250.0
Milestone Payments, Success-based Regulatory | Shanghai Junshi Biosciences Co., Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	15.0
Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt® | Non-CHINA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	825.0
Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt® | China
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	235.0
Roche | Milestone Payments, Development and Regulatory | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	180.0
Roche | Milestone Payments, Sales-based | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones capitalized	$ 1,030.0

X

- Definition

Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.

+ References

No definition available.

+ Details

Name:	lly_CollaborativeArrangementRightsAndObligationsPercent
Namespace Prefix:	lly_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Terms or rights and obligations under collaborative arrangements.

+ References

No definition available.

+ Details

Name:	lly_CollaborativeArrangementRightsAndObligationsRightsObligations
Namespace Prefix:	lly_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Collaborative Arrangement, Rights And Obligations, Terms, Annual Net Sales Threshold

+ References

No definition available.

+ Details

Name:	lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold
Namespace Prefix:	lly_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_CN
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_JardianceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_TrajentaBIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_BasaglarMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_OlumiantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_TYVYTMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_TanezumabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=lly_OutsideUSAndJapanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_LebrikizumabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=lly_JunshiBiosciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=lly_InnoventBiologicsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=lly_NonCHINAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=lly_RocheMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: